<DOC>
	<DOCNO>NCT00718120</DOCNO>
	<brief_summary>This study evaluate immunogenicity safety GSK Biologicals ' Trivalent split virion influenza vaccine Fluviral 2008-2009 season adult age 18 .</brief_summary>
	<brief_title>Immunogenicity Safety Study GSK Biologicals ' Fluviral® ( 2008 - 2009 Season ) Adults Over 18 Years</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . Male female adult , 18 60 year age 60 year age . Written inform consent obtain subject . Satisfactory baseline medical assessment history physical examination . Comprehension study requirement , ability comprehend comply procedure collection safety data , express availability require study period , ability willingness attend schedule visit . Acute disease time enrollment . Significant acute chronic , uncontrolled medical psychiatric illness . Any confirm suspected immunosuppressive condition include : History human immunodeficiency virus ( HIV ) infection , Cancer treatment cancer , within 3 year study enrollment . Persons history cancer diseasefree without treatment 3 year eligible . History renal impairment . History hepatic dysfunction due hepatitis B , C toxins include alcohol . Complicated insulindependent diabetes mellitus . Unstable cardiopulmonary disease require chronic medical therapy associate functional impairment . Presence blood dyscrasia , include hemaglobinopathies myelo lymphoproliferative disorder . Receipt systemic glucocorticoid within 1 month study enrollment , cytotoxic immunosuppressive drug within six month study enrollment . Inhaled topical steroid allow . A history demyelinate disease include Multiple Sclerosis GuillainBarré syndrome . Presence active neurological disorder . History chronic alcohol consumption and/or drug abuse . Any significant disorder coagulation increase risk intramuscular injection treatment coumadin derivative heparin . Persons receive prophylactic antiplatelet medication , e.g . lowdose aspirin , without clinicallyapparent bleeding tendency eligible . Receipt influenza vaccine within 6 month prior study enrollment . Administration vaccine within 30 day prior study enrollment study period . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede vaccination plan use study period . Administration immunoglobulins and/or blood product within three month precede administration study vaccine plan study . Any known suspected allergy constituent vaccine . A history severe adverse reaction previous influenza vaccination . If subject female , must nonchildbearing potential , childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution duration study . Lactating/nursing female . Any condition , opinion investigator , prevents subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Fluviral</keyword>
	<keyword>Influenza</keyword>
</DOC>